Virtual Interaction With Experts: Exploring Novel Therapeutics in Acute Myeloid Leukemia

In this virtual program faculty experts explore the use of investigational immunotherapeutic agents including monoclonal antibody&ndash based therapy immune checkpoint inhibitors vaccines and adoptive cell&ndash based therapy in treating patients with AML. Management of treatment-related toxicities will also be presented.

Share

Program Content

Activities

SOC Tx: elderly AML pts
Standard of Care Therapy for Elderly Patients with AML in 2020
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 16, 2020

Expires: July 15, 2021

Investigational Tx in AML
Investigational Agents and Combinations for AML
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: July 16, 2020

Expires: July 15, 2021

Activities

Novel Therapeutics in AML
Virtual Interaction With Experts: Exploring Novel Therapeutics in Acute Myeloid Leukemia
Congratulations: You achieved a completion on 04/09/2022

Faculty

cover img faculity

Richard Dillon, MD

Clinical Senior Lecturer
Department of Medical & Molecular Genetics
Kings Hospital, London
Consultant Haematologist
Department of Haematology
Guys Hospital
London, United Kingdom

cover img faculity

Guillermo Garcia-Manero, MD

Professor, Division of Cancer Medicine
Chief, Section of Myelodysplastic Syndromes
Division of Cancer Medicine
Department of Leukemia
The University of Texas MD Anderson Cancer Center
Houston, Texas

Supporters

Supported by an independent grant from

Helsinn Healthcare SA